DEF 14A: ADMA Biologics Sets Date for 2024 Annual Stockholders Meeting

ADMA Biologics will hold its annual stockholders meeting virtually on June 4, 2024, to vote on director elections and auditor ratification.

Summary

• ADMA Biologics, Inc. will hold its 2024 annual meeting of stockholders virtually on June 4, 2024, at 10:00 a.m. Eastern Time.
• Stockholders of record as of April 8, 2024, are entitled to vote at the meeting.
• The meeting will include proposals to elect three Class II directors, ratify the appointment of CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and transact other business.
• The Board of Directors recommends voting FOR all proposals.
• The proxy statement and annual report are available online, and stockholders can request printed copies.
• The company had 231,771,523 shares of common stock outstanding as of the record date, held by 13 holders of record.
• The election of directors requires a plurality of votes, while the auditor ratification requires a majority of votes cast.
• The Board held 8 meetings during the fiscal year ended December 31, 2023.
• The company's executive offices are located in approximately 4,200 square feet of space at 465 State Route 17, Ramsey, New Jersey 07446.
• The deadline for submission of stockholder proposals for the 2025 annual meeting is December 12, 2024.

Sentiment

Score: 7

Explanation: The document is primarily factual and procedural, with a positive outlook expressed by management regarding the company's leadership and governance. The sentiment is neutral to slightly positive.

Positives

• The company is providing a virtual annual meeting to facilitate stockholder attendance and participation.
• The Board of Directors is recommending stockholders vote FOR all proposals.
• The company has a process for stockholders to communicate directly with the Board.
• The company has a Code of Ethics and Business Conduct Standards applicable to all directors, officers, and employees.
• The company's Audit Committee requires pre-approval of all audit and non-audit services.

Negatives

• Adam S. Grossman is serving as Interim Chief Financial Officer while the company searches for a full-time replacement.
• Brian Lenz transitioned from Executive Vice President and Chief Financial Officer to a consulting role, indicating a change in leadership.
• There was a late Form 4 filed on behalf of Mr. Adam S. Grossman on March 8, 2023, with respect to three transactions that were not reported on a timely basis, and a late Form 4 filed on behalf of Mr. Brian Lenz on March 8, 2023, with respect to three transactions that were not reported on a timely basis.

Risks

• The proxy statement notes that the Auditor Ratification Proposal is advisory only and not binding on the company or the Board.
• The company's success depends on the continued service of qualified incumbents on the Board.
• The company's compensation practices are reviewed to confirm they do not create risks likely to have a material adverse effect.
• The company's Related Party Policy is reviewed with the Board of Directors or a sub-committee annually.

Future Outlook

The company has initiated an executive search for a full-time replacement Chief Financial Officer.

Management Comments

• Adam S. Grossman, President, Chief Executive Officer, Interim Chief Financial Officer and Director, thanks stockholders for their continued support.
• The Board believes that its current leadership structure provides the most effective leadership model for the Company.

Industry Context

The document mentions that the Compensation Committee reviews the company's compensation practices by comparing them with peer companies in the life sciences sector.

Comparison to Industry Standards

• The document mentions that the Board includes members who are designated nominees of certain stockholders, which is a common practice in companies with significant investors.
• The company's compensation practices are compared with peer companies in the life sciences sector, which is a standard practice for ensuring competitive compensation packages.
• The document references Nasdaq listing rules and SEC regulations, indicating compliance with industry standards for corporate governance and financial reporting.

Management Changes

Corporate Governance

Related Party Transactions

• The company operates under a Shared Services Agreement with Areth for office and warehouse space, paying $120,000 in 2023 and 2022.
• The company purchased specialized medical equipment and services from GenesisBPS and its affiliates, totaling $0.4 million in 2023 and $0.2 million in 2022.

Stakeholder Impact

• Stockholders are asked to vote on key proposals, impacting the company's governance and financial oversight.
• Employees may be affected by changes in executive leadership and compensation policies.
• The company's relationships with suppliers and service providers could be influenced by related party transactions.

Next Steps

• Stockholders are urged to vote on the proposals presented in the proxy statement.
• The company will hold its annual meeting on June 4, 2024.
• The company will continue its search for a full-time Chief Financial Officer.

Key Dates

Keywords

proxy statement, annual meeting, directors, auditor, stockholders, ADMA Biologics, governance, compensation, voting, shares